Table 1. Baseline characteristics of upper gastrointestinal bleeding case subjects and control subjects
Case subjects (n=630) Case subjects (n=630) Control subjects (n=1882) Control subjects (n=1882)
n % n % p-value
Age, years 0.93
65-74
176
27.9
540
28.7
75-79
173
27.5
515
27.4
80+
281
44.6
827
43.9
Mean (SD)
79.0
(6.0)
78.8
(6.0)
0.51
Women 290 46.0 866 46.0 0.99
Comorbiditities in the past two years
Diabetes
246
39.1
510
27.1
<.0001
Hypertension
483
76.7
1255
66.7
<.0001
Hyperlipidemia
92
14.6
269
14.3
0.85
CAD
214
34.0
556
29.5
0.04
Liver cirrhosis
61
9.7
87
4.6
<.0001
COPD
211
33.5
406
21.6
<.0001
Renal disease
79
12.5
83
4.4
<.0001
CKD
60
9.5
59
3.1
ESRD
19
3.0
24
1.3
Cancer
147
23.3
313
16.6
.0002
Prescribed drugs in the past year
Antiplatelet
360
57.1
855
45.4
<.0001
Aspirin
252
40.0
603
32.0
0.0003
Clopidogrel
49
7.8
96
5.1
0.01
Thienopyridines
0
0.0
0
0.0
OAC
24
3.8
41
2.2
0.03
NSAID
367
58.3
958
50.9
0.001
SSRI
Fluoxetine
304
48.3
810
43.0
0.02
Citalopram
150
23.8
492
26.1
0.25
Paroxetine
110
17.5
415
22.1
0.01